(dpa-AFX) VENLO – Qiagen (ETR:QIA), a provider of laboratory services and diagnostic expertise, has achieved success in the US. The business said late Monday night that a companion diagnosis has received approval from the U.S. Food and Drug Administration. Therascreen PDGFRA kit, according to the company, aids medical professionals in locating individuals with gastrointestinal stromal tumors who can benefit from Ayvakit (avapritinib) therapy.
Investors reportedly thought the news was good. Shares of Qiagen increased by 3% in after-hours U.S. trading in comparison to their Wall Street closing price.